33458-93-4
33458-93-4
Chemical Structure
AH 6809
- CAS No.: 33458-93-4
- Formula:C17H14O5
- Molecular Weight:298.29
IUPAC Name: 6-isopropoxy-9-oxo-9H-xanthene-2-carboxylic acid
InChIKey: AQFFXPQJLZFABJ-UHFFFAOYSA-N
SMILES: O=C1C2=C(C=CC(C(O)=O)=C2)OC3=CC(OC(C)C)=CC=C31
Biological Activity: AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AH 6809 | 99.57% | AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AH 6809 (Standard) | ≥98% | AH 6809 (Standard) is the analytical standard of AH 6809. This product is intended for research and analytical applications. AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Abramovitz M, et, al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. [Content Brief]
- [2]. Kiriyama M, et, al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [Content Brief]
- [3]. Woodward DF, et, al. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochem Pharmacol. 1995 Nov 9;50(10):1731-3. [Content Brief]
Keywords
